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Summary The value of neuron specific enolase (NSE) immunoreactivity as a marker for small cell lung
cancer (SCLC) has been assessed using a monoclonal antibody (MCAB) against NSE. MCAB specificity was
confirmed using purified enolase isoenzymes, sections of human brain, a panel of lung tumours,
neuroendocrine and non-neuroendocrine tumours and normal tissues. Using this MCAB in radioimmunoassay
and immunohistochemistry, NSE immunoreactivity was detected in all SCLC material examined. However,
considerable reactivity was also observed in a number of non-small cell lung cancer cell lines and tumour
biopsy specimens. Furthermore, intratumoral heterogeneity with respect to NSE immunostaining was
observed in several cases. Factors which may underlie such intratumoral phenotypic diversity were assessed
using flow cytometry together with MCABs directed against both NSE and non-neuronal enolase. Such
studies revealed that enolase expression in cells which were no longer actively proliferating differed markedly
from that of cells in exponential growth. Furthermore, cells grown under conditions of increasing hypoxia
exhibited increased enolase expression relative to those grown under oxygenated conditions. It is concluded
from these studies that NSE immunoreactivity per se is an unreliable marker for the SCLC phenotype.
The glycolytic enzyme enolase is ubiquitous in its
distribution and necessary for the anaerobic
conversion of glucose to metabolites suitable for
oxidation. The enzyme has three distinct subunits
designated a, # and y. Five forms of the enzyme
have been demonstrated (Rider & Taylor, 1974;
Fletcher et al., 1976; Marangos et al., 1978). These
include the three homodimers axa, /3/ and yy and
two hybrids 4f and oy. The 3 enolase form is found
predominantly in muscle. The cx-isoenzyme, termed
non-neuronal enolase (NNE) is the commonest
form occurring in most adult tissues. The y-form is
a specific marker for neurons in the central and
peripheral nervous system and has been designated
neuron-specific enolase (NSE) (Schmechel et al.,
1978a). NSE is also present in the peripheral neuro-
endocrine cells of the amine precursor uptake and
decarboxylation (APUD) classification (Schmechel
et al., 1978b) and is highly localised in neuro-
endocrine peptide secreting cells of gut (Facer et al.,
1980), pancreas (Schmechel et al., 1978b) and skin
(Gu et al., 1981). Highly elevated levels of NSE are
also found in tumours designated APUD omas
which are thought to arise from these cells (Tapia et
al., 1981). Tumours such as glucagonomas,
pheochromocytomas, insulinomas and melanomas
have all been shown to be high in NSE. Small cell
carcinoma of the lung (SCLC) is considered to be a
neuroendocrine type tumour (Bensch et al., 1968;
Gould et al., 1983; Carter, 1983) and elevated levels
Correspondence: J.G. Reeve.
Received 28 October 1985; and in revised form, 18
December 1985.
of NSE have been found in SCLC compared to
non-small cell lung cancer (NSCLC) by some
workers (Schmechel et al., 1978b; Marangos et al.,
1982; Springall et al., 1984). It has been suggested
that NSE immunostaining may facilitate greater
accuracy in the cytological diagnosis of SCLC.
However, more recently it has been found that
immunostaining for neural markers, including NSE,
is of little value in the positive identification of
SCLC by endobronchial biopsy since a significant
number of NSCLC tumours were positively stained
for NSE (Dhillon et al., 1985). Furthermore,
considerable intratumoral heterogeneity with
respect to NSE immunostaining has also been
observed in SCLC tumours, with some cells
showing strong, and others little, staining (Dhillon
et al., 1985; Wilson et al., 1985). Clearly the clinical
usefulness of NSE as a diagnostic adjunct for the
positive identification of SCLC is a matter of some
controversy.
In the present study we further assess the value of
NSE immunoreactivity as a marker for SCLC using
a monoclonal antibody (MCAB) against NSE.
Furthermore, factors which may underlie
intratumoral phenotypic diversity in the expression
of both NSE and NNE have also been assessed
using flow cytometry and MCABs directed against
these isoenzymes. Since enolase expression is a
parameter of the energy production capacity of a
tumour cell, the effects of growth phase, cell cycle
phase and oxygenation status have been assessed.
MCAB specificity has been evaluated against
purified enolase isoenzymes and sections of human
brain, a panel of lung tumours, neuroendocrine and
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non-neuroendocrine tumours and against a
selection of normal tissues.
Materials and methods
Antigens
Purified human NSE and non-neuronal enolase
(NNE) was generously donated by Dr R.
Thompson (Clinical Biochemistry Department,
Cambridge, England).
Tumour cells
Lung tumour cultures used in this study include
several recently derived in this laboratory from
clinical material. The phenotypic characteristics of
these cells are fully described elsewhere (Baillie-
Johnson et al., 1985). All SCLC cultures designated
COR-L were derived from patients clinically
diagnosed as having SCLC; NSCLC COR-L23 was
derived from a patient having large cell carcinoma
of the lung. Established SCLC lines FRE, MAR,
POC and NSCLC lines MOR and BEN were
kindly donated by Dr M. Ellison (Ludwig Institute,
Sutton, England). NCI-H69 was donated by Dr D.
Carney (NCI, Bethesda, USA) and was derived
from a SCLC patient.
A variety of widely available human tumour cell
lines were also used in this study (Tables II-III).
CAMA-1, KB and Colo 320 were obtained from
Dr E. Lennox, MRC Centre, Cambridge, England.
Raji and Molt 4 were provided by Professor P.
Lachmann, MRC Centre, Cambridge, England. All
other cell lines were generously donated by Dr
M.J. Embleton, CRC Laboratories, Nottingham,
England.
In vitro immunization
The spleen from a female BALB/C mouse aged
between 8-12 weeks (Olac 1976, Oxford) was
aseptically removed following cervical dislocation.
Splenic lymphocytes were harvested by applying
gentle pressure to the spleen with a syringe plunger
in a petri dish containing 10ml Hank's Balanced
Salt Solution (HBSS). Larger tissue fragments were
allowed to settle out and the cell suspension was
centrifuged at 300g. The pelleted lymphocytes were
resuspended at a density of 107ml- in Dulbecco's
modified Eagle's medium (DMEM) (Imperial
Laboratories Ltd) supplemented with 20% foetal
calf serum (FCS) (Sera Lab), 5 x 10- M 2-mer-
captoethanol, 2mM glutamine, 1 mM sodium
pyruvate, 100Uml-1 penicillin and 100pgml-1
streptomycin (Gibco Biocult Ltd) and placed in
75cm2 tissue culture flask (Falcon). For the
immunization 10jg of purified soluble antigen
(NSE) was added to the culture together with
20jgml-1 of N-acetylmuramyl-L-alanyl-D-isoglut-
amine (Sigma) (Boss, 1984). The cells were
incubated at 37°C in a humidified 10% C02/90%
air atmosphere for 4 days prior to fusion.
Cellfusion
Lymphocytes were recovered from culture, washed
twice in DMEM containing 2.5% FCS and
followed by a single wash in serum free medium.
The non-secreting mouse myeloma P3NSO-Ag4.1
(kindly supplied by Dr C. Milstein, MRC Centre,
Cambridge, England) was used in cell fusions.
P3NSO-Ag4.1 cells were washed as described above
prior to fusion. Cultured lymphoid cells (_ 107)
were then mixed with 2 x 106 washed P3NSO cells
and the mixture was washed once in serum-free
medium. Fusions (Galfre & Milstein, 1981) were
performed using polyethylene glycol 1540 (Koch-
Light Laboratories). The fusion mixture was
dispensed into a 96-well microtitre plate (Falcon)
and grown in DMEM supplemented with 20%
FCS, 2mM glutamine, 1 mM sodium pyruvate,
100Uml -1 penicillinand 100,ugml -1 streptomycin at
37°C, in a humidified 10% CO2/90% air atmosphere.
Twenty-four hours after fusion cells were fed with
growth medium containing 100jM hypoxanthine,
16jM thymidine and 0.4uM aminopterin (Sigma).
Supernatant medium from microtitre wells
containing hybridomas was tested for antibodies to
NSE using an antibody detection assay.
Antibody detection assay
Disposable polyvinylchloride microtitre plates
(Falcon) were coated with 50MI of 10jgml 1 NSE
in 0.1 M carbonate bicarbonate buffer, pH9.6 by
incubation at 37°C for 2h. Plates were washed
twice with PBS and the wells coated with PBS-I %
bovine serum albumen (PBS-BSA). PBS-BSA was
removed from the wells, replaced with hybridoma
supernatants diluted 1:5 in PBS-BSA and the wells
were incubated for 1 h at room temperature. After
washing, wells were incubated for 1 h at room
temperature with pooled rabbit anti-mouse 1 gG
and anti-I gM (Miles Laboratories) each diluted
1:1,500 in PBS-BSA. Wells were washed twice with
PBS, incubated for 1 h with 125I-protein A
(50,000 counts per minute/well) (New England
Nuclear) and finally washed 5 times with PBS.
Individual wells were cut with a hot wire device
and counted in a gamma counter. To determine the
specificity of antibodies produced by hybridomas,
supernatants were also screened against NNE.
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repeatedly minicloned (Nowinski et al., 1979) in
order to stabilize antibody production. Cells from
each positive well were diluted with splenocyte
feeder cells and reseeded into 96 wells of a micro-
titre plate at a concentration of 5 cells per well.
This procedure was repeated until more than 95%
of the wells with growth gave a positive antibody
signal. The cells were then strictly cloned in semi-
solid agar and 10 days later individual clones were
isolated and transferred to individual wells of a 24-
well plate (Falcon). Supernatant medium was then
retested against NSE and NNE by the previously
described radioimmunoassay (RIA).
Immunodiffusion
Ouchterlony immunodiffusion was performed in
1% Difco Noble Agar in 0.9% sodium chloride.
Ten-fold concentrated hybridoma supernatant was
screened against rabbit anti-mouse subclass
immunoglobulins (Miles Laboratories).
Immunohistochemistry
Brain sections Human brain specimens were fixed
in 4% paraformaldehyde. For immunoperoxidase
staining, sections were treated sequentially with (i)
5% hydrogen peroxide (H202) for 30min; (ii)
running tap water and distilled water for 10 and
5min respectively; (iii) 50mM Tric-HCl buffered
saline, pH7.6 containing 2% normal sheep serum
(Tris/NaCl/sheep serum) for 1h; (iv) hybridoma
supernatant for 72h at 4°C; (v) three 10min washes
in Tris/NaCl; (vi) peroxidase-conjugated sheep anti-
mouse 1gM (Miles Laboratories) diluted one
hundred fold in Tris/NaCl/sheep serum for 1 h at
room temperature; (vii) three 10min washes in
Tris/NaCl; (viii) 0.05% DAB/0.06% H202 in
Tris/NaCl for 5min at room temperature and
finally (ix) running tap water for 5min. P3NSO-
Ag4.1 spent medium and dilute normal mouse
serum were used as controls for MCAB B12/A6.
Tumour cells Washed aggregates from suspension
cultures of SCLC COR-L32, NCI-H69 and POC
were mechanically disaggregated to yield single cell
suspensions. Cells were cytospun onto poly-L-lysine
coated slides and fixed in 4% paraformalde-
hyde/0.05% glutaraldehyde in 0.1M borate buffer,
pH9.5 for 30min. After three washes in buffer,
cells were treated sequentially with (i) 2% sheep
serum/PBS for 10min; (ii) hybridoma supernatant
overnight at 4°C; (iii) three 5min washes in PBS;
(iv) fluorescein-labelled sheep anti-mouse 1gM
(Miles Laboratories) diluted 1:100 in PBS for
45min at room temperature; (v) three 10min
washes in PBS. Slides were cover-slipped in
PBS/glycerol and viewed with an Olympus
fluorescence microscope. Controls included
replacing MCAB B12/A6 with an irrelevant mouse
monoclonal antibody of the 1 gM class.
Normal tissues and tumour biopsy specimens
Normal tissues were obtained within 2h of post
mortem. Frozen sections, 5,um in thickness, were
prepared and subsequently fixed in 4%
paraformaldehyde. Paraffin embedded, formal
saline fixed tumour biopsy specimens were obtained
from the files of Papworth Hospital (Papworth,
UK). Indirect immunoperoxidase staining was
carried out as described for brain sections.
Radioimmunochemical localization in human tumours
and other tissues A variety of human tumour and
normal tissues were screened for NSE
immunoreactivity using a solid phase system in
which 105 fixed cells were placed into the wells of a
96-well microtitre plate. Cells were then treated
sequentially with (i) PBS-BSA for 10min at room
temperature; (ii) MCAB B12/A6 or P3NSO-Ag4.1
supernatant diluted 1:5 in PBS-BSA; (iii) three
washes in PBS; (iv) rabbit anti-mouse 1 gM diluted
1:1,500 in PBS-BSA; (v) three washes PBS; (vi)
50,000 counts per minute 1251 protein A in PBS-
BSA; (vii) six washes PBS. Individual wells were
counted in a gamma counter.
Flow cytometry
The Cambridge dual laser flow cytometer (Watson,
1980,1981) with a high efficiency light collection
flow chamber (Watson, 1985) was used in all cell
studies. The Innova-90 argon ion laser (Coherent,
Palo Alto, California, USA) was tuned to the
488nm line at a light power of 100mW to excite
DNA stained with propidium iodide (5mgml-1,
Calbiochem Ltd) and fluoresceinated antibodies.
Light was analysed on four photodetectors
simultaneously, namely forward and 900 scatter
plus fluorescence on the red (DNA) and green
(fluorescein) channels. The data were collected list
mode on a fast RPO7 disc via a dedicated LSI
11/23 and a time changing PDP 11/40 computer
and subsequently analysed on a VAX 11/780
computer (all Digital Equipment Corporation). The
scatter signals were used to gate out debris and
clumps and the medians of the green fluorescence
distributions were determined. The latter were
calculated for either the whole population or in
association with the GI, S or G2 and M regions of
the DNA histograms. The proportions of cells in
the GI, S and G2 and M regions of the DNA
histogram were calculated with a cell cycle model
(Watson, 1985b).
Comparison ofNSE immunostaining in cells growing
in logarithmic and plateau phase of cell growth
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NCI-H69 in either exponential or plateau phase of
growth (determined from growth curves) were
mechanically disrupted and fixed in 4%
paraformaldehyde. Indirect immunofluorescence
staining was carried out on cells in suspension as
described previously and assessed by flow
cytometry.
Comparison of NSE immunostaining in cells grown
under hypoxic or oxygenated conditions To
evaluate the effect of hypoxia on NSE immuno-
staining NCI-H69 cells in exponential growth were
exposed to continuous nitrogen gas exposure for
periods ranging from 1 h to 24h. Indirect immuno-
fluorescence staining was carried out on para-
formaldehyde fixed cells as described previously
and assessed by flow cytometry.
Results
In vitro immunization and cellfusion
Hybridoma populations were detected in all 96
wells of the microtitre plate seeded with the fusion
mixture. Of these 36% reacted positively with NSE
in RIA and 10 were selected for minicloning.
Miniclones retested for specific antibody production
varied considerably in the number of antibody
positive wells; however, after 2 cycles of
minicloning almost all the wells were positive for
antibody production. Following agar cloning 192
agar clones were picked and screened against NSE
and NNE. Of these 87.5% produced antibody that
reacted with both antigens. The remainder were
relatively specific for NSE. One antibody from each
category was selected for further study.
Immunodiffusion
MCABs B12/A6 and C6/14 are of the 1 gM
subclass.
Characterisation ofthe MCABs
Isoenzyme specificity The reactivities of MCABs
B12/A6 and C6/14 with NSE and NNE as
determined by the RIA are shown in Table I. It can
be seen that for MCAB B12/A6, incubation with
NSE produced significantly increased binding of
125I-protein A over levels detected with P3NSO-
Ag4.1 medium. In contrast, incubation of NNE
with this MCAB only marginally increased 1251_
protein A binding. However, the reactivity of
MCAB C6/14 with NSE is no different from that
of NNE.
Table I Reactivity of MCABs B12/A6 and C6/14 with
NSE and NNE
Mean 125I c.p.m. +s.d.
Test supernatant NSE NNE
P3NSO-Ag4.1
(spent medium) 200.8+60.0 183.3+45.0
MCAB B12/A6 3,810.0+310.7 425.8+14.1
MCAB C6/14 5,336.0+217.9 5,391.6+ 51.7
Immunohistochemical staining of brain material and
other normal tissues Using the immunoperoxidase
method on sections of human striatum, MCAB
B12/A6 stained neurons and neuronal processes
strongly (Figure 1). Glial cells and fibrous
astrocytes were unstained. The subcellular
localization of antibody B12/A6 was
characteristically cytoplasmic with no staining over
the nucleus.
Figure 1 Immunoperoxidase localisation of NSE in human brain by MCAB B12/A6. Nerve cell bodies show
cytoplasmic localisation ofNSE with no staining over the nucleus (N). Arrows indicate neuronal process.NSE EXPRESSION IN LUNG CANCER 523
MCAB B12/A6 failed significantly to stain
foetal spleen, skeletal muscle, bladder, colon,
submandibular gland, liver and skin. NSE immuno-
reactivity was detected by this antibody in the
chromaffin cells of the adrenal medulla and in
pancreatic islet cells.
MCAB C6/14 stained both neurons and glial
cells of human brain, the latter cells being rich in
NNE. This MCAB gave some staining on most
normal tissues and failed to selectively stain neuro-
endocrine cells. MCAB C6/14 reacted particularly
well with liver which has also been shown to be
rich in NNE-like enzyme.
Radioimmunochemical localization of NSE in cell
cultures of human tumours and other tissues The
binding of MCAB B12/A6 against a panel of
human tumour cell cultures is shown in Tables II
and III. MCAB B12/A6 showed extensive reactivity
with all SCLC material examined. Binding to other
lung tumour histological types examined was
variable and was always less than that to SCLC
material; for exanple COR-L23 (large cell) and
MOR (adenocarcinoma) showed significant binding
of the antibody but A549 (bronchioalveolar
carcinoma) showed low levels of reactivity. All non-
neuroendocrine tumours examined similarly showed
Table II Binding of MCAB B12/A6
cancer cell lines
to human lung
Human lung cancer % Specific
Type cell lines binding8
Small cell FRE 18.2
MAR 22.4
POC 15.8
H69 26.3
COR-L24 18.1
COR-L27 16.3
COR-L31 16.9
COR-L42 18.5
COR-L47 21.5
COR-L51 16.0
COR-L54 18.1
COR-L71 16.2
COR-L80 18.5
Large cell COR-L23 9.7
Adenocarcinoma MOR 8.4
A549 2.4
A427 6.1
Squamous BEN 12.1
a% Specific binding=(c.p.m. bound by MCAB-c.p.m.
bound by P3NSO spent medium/input c.p.m.)x 100.
Values represent the mean of triplicate determinations,
from within a single experiment, which varied by less than
5%. Similar data were obtained consistently on several
independent occasions.
Table III Binding of MCAB B12/A6 to non pulmonary
tumour cell lines
% Specific
Type Target cell binding8
Osteogenic sarcoma U393-OS 4.9
Osteogenic sarcoma T278 4.6
Colon carcinoma HCT8 4.8
Prostate carcinoma EB33T 4.1
Ovarian carcinoma PA-1 5.6
Bladder carcinoma T24 2.3
Cervical carcinoma HeLa 2.2
Breast carcinoma CAMA-1 4.2
Epidermoid carcinoma KB 2.4
B Lymphoblastoid Raji 2.1
T Lymphoblastoid Molt 4 1.5
Melanoma Mel 57 13.4
NK 14 12.4
RPMI 5966 11.8
Neuroendocrine tumour
of colon Colo 320 8.7
'See Table II for calculation.
little binding of the antibody. The three melanomas
examined did show elevated reactivity with MCAB
B12/A6, as did Colo320 a neuroendocrine tumour
of the colon. Normal embryonic lung, peripheral
lymphocytes and red blood cells failed to show
significant binding.
Enolase immunostaining in SCLC and NSCLC
tumour biopsy specimens All 9 SCLC tumour
biopsy specimens gave staining with MCAB
B12/A6 although this was heterogenous with
respect to intensity and in one case (SCLC 6),
localization (Figure 2). Considerable heterogeneity
of staining was also observed with the three
squamous cell carcinomas examined (Figure 3). An
adenocarcinoma of the lung and a mesothelioma
were negative, as were an adenocarcinoma of the
stomach and a basal cell carcinoma. However,
considerable immunoreactivity was observed with a
melanoma.
Sections of SCLC and squamous cell carcinoma
stained with MCAB C6/14 showed patterns of
heterogeneity similar to those obtained with MCAB
B12/A6 with some cells staining strongly and others
showing little or no staining.
Enolase immunostaining in SCLC cultures
Considerable cellular heterogeneity in the
expression of neuron specific enolase was seen when
spheroids 200-300 jim diameter were mechanically
disaggregated and stained with MCAB B12/A6
using immunofluorescence. Figure 4a,b shows such
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Figure 2 Small cell carcinoma, oat cell type.
Immunoperoxidase staining for NSE using MCAB
B12/A6. Note moderate overall staining with cells in
some areas showing strong and others showing little
staining.
Figure 3 Squamous cell carcinoma (lymph node
metastasis). Immunoperoxidase staining for NSE using
MCAB B12/A6. This tumour showed considerable
cellular heterogeneity with respect to NSE
immunostaining with some cells being intensely stained
and others showing little or no staining. Note that
normal lymph node cells are unstained by the MCAB.
a preparation under phase contrast and fluorescence
microscopy and illustrates considerable cell-cell
variations in fluorescence-staining. Similar results
were obtained using MCAB C6/14, with some
SCLC staining intensely and others showing little
or no staining. All controls were negative.
Factors affecting tumour cell heterogeneity in enolase
expression in vitro
Growth phase Cell cycle distribution analyses using
flow cytometry in SCLC cultures growing in
exponential and plateau phase of growth are shown
in Table IV. Cell viability was assessed by trypan
blue exclusion and was found to be not significantly
different for cells in exponential or plateau growth
Figure 4(a) Cells from SCLC cell line NCI-H69
viewed under phase contrast. Cells have been fixed,
reacted with MCAB B12/A6 and processed for
immunofluorescence as described in Materials and
methods.
(b) The same cells shown in (a) viewed by
fluorescence microscopy. Considerable variation in
fluorescence staining can be seen throughout and is
particularly well exemplified in cells numbered 1-5.
Table IV Cell cycle distributions of SCLC
cells in exponential and plateau growth
phase
% Cell number
Cell cycle stage Exponential Plateau
GI 33.5 61.8
S 36.0 0
G2 30.5 38.2
(data not shown). It can be seen from Table IV that
in contrast to cells in exponential growth, cells
which have reached plateau are arrested in G1 and
G2 with no or very few cells in S phase. Figure 5
shows the reactivity of such cultures with MCABNSE EXPRESSION IN LUNG CANCER 525
A
A
4 10
:LI
cn
c
.)
c
a)
n
c
C.)
0
C,, a)
0
Antibody concentration (x-fold)
Figure 5 Reactivity of SCLC NCI-H69 cells in
exponential or plateau growth phase with MCAB
B12/A6 as determined by immunofluorescence and
flow cytometry. Each point represents the median
fluorescence intensity associated with 10,000 cells.
MCAB supernatants were concentrated by ammonium
sulphate precipitation followed by solubilisation and
dialysis. A cells in exponential growth; * cells in
plateau growth phase.
B12/A6 as determined by flow cytometry. It can be
seen that when cells are reacted with various
dilutions of MCAB B12/A6 fluorescence intensity (a
measure of MCAB binding) is significantly greater
in cells in exponential growth than in cells which
have reached plateau growth. Similar data were
obtained for cells stained with MCAB C6/14. No
differences in fluorescence intensity of log phase and
plateau phase cells stained with an irrelevant
MCAB were observed.
Cell cycle phase Figure 6 shows flow cytometric
analysis of NSE expression for cells in different
stages of the cell cycle. It can be seen that there are
no major differences in the expression of NSE for
cells in G1, S and G2 of the cell cycle. Similar data
were obtained for cells reacted with MCAB C6/14.
Oxygenation status As enolase is a key enzyme in
the anaerobic conversion of glucose, the effects of
increasing periods of hypoxia on enolase levels was
assessed using indirect immunofluorescence and
flow cytometry. It can be seen from Figure 7 that
the effect of increasing hypoxia was dramatically to
increase the fluorescence intensity of cells which had
been reacted with MCABs B12/A6 and C6/14. In
contrast, no change in fluorescence intensity with
1 4 10
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Figure 6 NSE expression in SCLC NCI-H69 cells in
different stages of the cell cycle. Cells were reacted with
MCAB BI2/A6 followed by FITC-conjugated rabbit
anti-mouse gM. Cells were then stained with
propidium iodide solution for cell cycle analyses. The
fluorescence intensity associated with cells in Gl, S
and G2 was determined by gating appropriate
channels. Each point represents the median
fluorescence intensity associated with 10,000 cells.
* cells in Gl; A cells in G2; * cells in S.
increasing hypoxia was observed when cells were
reacted with an irrelevant MCAB of the 1 gM
subtype. Cell cycle distribution analysis of hypoxia
treated cells showed that even after 24h continuous
exposure to nitrogen, cells were still actively
progressing through the cell cycle. The viability of
these cells was assessed by trypan blue exclusion
and was found to be no different from untreated
cells (data not shown).
Discussion
The distinction between SCLC and the other major
conventional histological types of lung cancer is of
major importance for clinical management. How-
ever, because of the heterogeneous nature of the
disease, particularly with respect to morphology, the
subclassification of malignancies into SCLC and
NSCLC may occasionally be difficult. The finding
that SCLC stained positively for NSE, a marker of
neuroendocrine cells (Schmechel et al., 1978b; Facer
et al., 1980; Gu et al., 1981), has prompted several
workers to propose this isoenzyme as a potential
marker of the SCLC phenotype (Springall et al.,
1984; Sheppard et al., 1984). However, a number of
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Figure 7 NSE expression in cells exposed to
increasing periods of hypoxia. Fluorescence intensity
increases dramatically in cells which have been reacted
with either MCAB B12/A6 (0) or with MCAB C6/14
(A) but fails to do so when an irrelevant MCAB of
the same subtype is used (0). Each point represents
the median fluorescence intensity associated with
10,000 cells.
observations support the view that SCLC and
NSCLC may be related through a differentiation
continuum, which probably reflects the
differentiation pathway of the bronchial epithelium
(Goodwin et al., 1983). It follows that the
neuroendocrine properties of SCLC including NSE
immunoreactivity need not be restricted to this
histology alone. In recent assessments of NSE
immunoreactivity in SCLC and NSCLC biopsies,
no evidence could be found for the specific
localisation of NSE in SCLC and it was concluded
from these studies that positive staining for
neuroendocrine markers did not assist in
distinguishing between SCLC and NSCLC biopsies
(Dhillon et al., 1985; Bergh et al., 1985). Similarly
NSE has been histochemically demonstrated in
several types of CNS tumours and in non-
neuroendocrine tumours including Schwannomas,
carcinoma and fibroadenoma of the breast, renal
cell carcinoma and chordoma (Vinores et al., 1984).
In the present study NSE immunoreactivity has
been assessed in cultures of SCLC and NSCLC and
in lung tumour biopsy specimens using a MCAB
directed against NSE, B12/A6. This MCAB is
specific for NSE and can therefore be used to
localise cells containing this enzyme. Thus in
sections of human brain, MCAB B12/A6 labelled
neurons and neuronal processes only, an
observation consistent with the accepted
localisation of NSE in the brain. It also stained
neuroendocrine cells of the pancreas and adrenal
medulla. Normal tissues, previously shown to
contain low levels of immunoreactive NSE, were
unstained by the MCAB.
In RIA, MCAB B12/A6 reacted extensively with
SCLC, clearly distinguishing this from the other
lung histologies examined and from normal
embryonic lung fibroblasts. However, the reactivity
of this MCAB with most of the NSCLC cell lines
examined was much greater than that with non-
pulmonary tumours and was equivalent to that seen
for neuroendocrine tumour cell lines such as
melanoma.
Similarly we could find no evidence to support
the view that NSE immunoreactivity per se
distinguishes SCLC from NSCLC when lung tumour
biopsies were assessed for immunoreactivity in
immunohistochemical assay. Whilst all SCLC
tumours examined stained positively for NSE using
MCAB B12/A6, staining intensity was variable and
for one SCLC tumour only localised regions of the
tumour were stained. Furthermore, all three
squamous cell lung carcinomas gave consistent but
patchy NSE staining.
Our findings concur with those of previous
workers (Bergh et al., 1985; Dhillon et al., 1985) and
do not support the view that NSE immunostaining
can be used as a diagnostic indicator for the SCLC
phenotype (Springall et al., 1984). Furthermore,
interpretation of histological sections stained for
NSE immunoreactivity can be complicated by
considerable intratumoral heterogeneity in the
expression of the enzyme as evidenced by variability
in cell immunostaining.
Such variability can be explained by genetic and
epigenetic differences between cells. Viable SCLC
cells, in which NSE is undetectable may, through
altered gene expression for example, maintain
glycolysis with enolase not of the neuron specific
type. However, it is clear from the data presented in
the present study that some apparently viable
SCLC cells fail to express immunodetectable NSE
and NNE as evidenced by their lack of reactivity
with MCAB C6/14. Since enolase expression is a
parameter of the energy production capacity of a
tumour cell, it is likely that the metabolic
requirements of these cells have been modified byNSE EXPRESSION IN LUNG CANCER 527
epigenetic factors. The quantitative data obtained
from flow cytometry supports this contention. Thus,
cells grown in vitro which had reached plateau
phase of growth and which were no longer actively
proliferating were found to express much lower
levels of enolase enzymes than cells in exponential
growth. The observation that cells grown under
conditions of increasing hypoxia have increased
enolase expression relative to those grown under
oxic conditions demonstrates further epigenetic
modification of NSE expression.
These findings suggest that it is likely that
enolase expression is related to microenvironmental
factors affecting the metabolic requirements of a
given cell within a tumour. If tumour cell
heterogeneity with respect to NSE expression is
indeed largely a manifestation of such factors then
on a pragmatic level, its value as a SCLC tumour
marker is highly questionable.
However, the data presented in this study suggest
that overall enolase expression, as detected by
MCAB C6/14, which recognised enolase enzymes
irrespective of isotype, is a reliable immuno-
histochemical indicator of the energy production
capacity of a tumour cell. Assuming that this is
related to viability, it may be possible to use this
MCAB to follow the effects of non-operative
treatment such as radiotherapy and chemotherapy
in lung cancer as suggested by previous workers
(Dhillon et al., 1982).
The authors gratefully acknowledge the excellent technical
assistance rendered by Mr J.J. Shaw, Ms K.A. Wright and
Ms N. Fox.
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